Dosing & Uses
Dosing Strengths & Forms
capsule
- 60mg
- 500mg
tablet
- 500mg
powder
- 2g
Supplement
12 g PO divided q4-6hr
Administration
Take with adequate liquid to avoid gastric upset
Dosing Strengths & Forms
capsule
- 60mg
- 500mg
tablet
- 500mg
powder
- 2g
Supplement
1g/10 pounds of weight/day PO in divided doses
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (3)
- sulfadiazine
aminobenzoate potassium decreases effects of sulfadiazine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- sulfamethoxazole
aminobenzoate potassium decreases effects of sulfamethoxazole by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- sulfisoxazole
aminobenzoate potassium decreases effects of sulfisoxazole by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
Monitor Closely (1)
- omadacycline
aminobenzoate potassium will decrease the level or effect of omadacycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.
Minor (0)
Adverse Effects
Frequency Not Defined
Anorexia
Nausea
Fever
Hepatotoxicity
Rash
Warnings
Contraindications
Hypersensitivity
Concomitant sulfonamide antibiotics (effects may be nullified)
Cautions
Stop therapy if anorexia occurs and reinitiate therapy once appetite improves
Stop therapy if nausea occurs and reinitiate therapy once patient improves
Use wiht caution in diabetes mellitus, hypoglycemia, or renal disease
Pregnancy & Lactation
Pregnancy Category: Not studied
Lactation: Unknown if excreted in breast milk; use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Related to B vitamins that may have antifibrotic effects by increasing oxygen uptake at tissues level
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Potaba oral - | 500 mg capsule |  |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
